iRadimed Corporation $IRMD Shares Sold by HighTower Advisors LLC

HighTower Advisors LLC reduced its holdings in iRadimed Corporation (NASDAQ:IRMD) by 49.5% during the 4th quarter, Holdings Channel reports. The firm owned 20,363 shares of the medical equipment provider’s stock after selling 19,998 shares during the quarter. HighTower Advisors LLC’s holdings in iRadimed were worth $1,981,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. SG Americas Securities LLC grew its holdings in iRadimed by 88.6% in the fourth quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock valued at $6,848,000 after purchasing an additional 33,072 shares during the period. Tudor Investment Corp ET AL acquired a new stake in iRadimed in the third quarter valued at approximately $666,000. Principal Financial Group Inc. purchased a new position in shares of iRadimed in the third quarter valued at approximately $422,000. Baader Bank Aktiengesellschaft purchased a new position in shares of iRadimed in the fourth quarter valued at approximately $595,000. Finally, RFG Advisory LLC purchased a new position in shares of iRadimed in the fourth quarter valued at approximately $1,594,000. 92.34% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other iRadimed news, CEO Roger E. Susi sold 2,500 shares of iRadimed stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $87.88, for a total value of $219,700.00. Following the sale, the chief executive officer owned 2,172,500 shares in the company, valued at $190,919,300. The trade was a 0.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 67,500 shares of company stock valued at $6,318,853 in the last quarter. 36.80% of the stock is owned by insiders.

iRadimed Stock Performance

Shares of iRadimed stock opened at $92.05 on Tuesday. iRadimed Corporation has a one year low of $55.11 and a one year high of $107.90. The company has a market cap of $1.18 billion, a price-to-earnings ratio of 50.30 and a beta of 0.90. The business’s 50 day moving average price is $91.71 and its 200 day moving average price is $95.47.

iRadimed (NASDAQ:IRMD) last posted its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.The company had revenue of $21.98 million for the quarter, compared to the consensus estimate of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. On average, analysts predict that iRadimed Corporation will post 1.52 EPS for the current fiscal year.

iRadimed Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, May 29th. Shareholders of record on Friday, May 15th were given a $0.20 dividend. The ex-dividend date was Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. iRadimed’s payout ratio is currently 43.72%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Freedom Capital upgraded iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd. Lake Street Capital restated a “buy” rating and issued a $120.00 target price on shares of iRadimed in a research report on Wednesday, February 11th. Roth Mkm restated a “buy” rating and issued a $120.00 target price on shares of iRadimed in a research report on Tuesday, February 10th. Finally, Weiss Ratings downgraded iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.